Skip to main content
OpenTrials
Completed

NCT Number: NCT02620254

Mast Cell Connect: A Registry for Patients With Mastocytosis

The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool. No experimental intervention is involved.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Mastocytosis is an extremely rare and heterogeneous spectrum of diseases characterized by the buildup of genetically altered mast cells. Patients experience a wide range of symptoms and in some cases, mast cell buildup can lead to organ dysfunction and failure. Current treatments address disease symptoms and not the underlying cause. To facilitate the development of new therapies for mastocytosis, it is important for the community to support clinical trials and to document the impact of the disease, including disease natural history and the impact on patients, in a systematic way. Mast Cell Connect is a web-based registry that allows mastocytosis patients and caregivers to enter information about the experience of the patient living with mastocytosis directly into an online data collection tool.

The Mast Cell Connect Registry allows mastocytosis patients and caregivers to enter information about the experience of the patient living with mastocytosis directly into a web-based data collection tool. Two forms of data will be collected: responses to surveys administered on the web-based portal, and de-identified data curated from medical reports uploaded by patients or their caregivers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient with a diagnosis of mastocytosis, including systemic mastocytosis and cutaneous mastocytosis and any subtypes of these diseases, who is willing and able to provide written online informed consent

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Further the understanding of the epidemiology of mastocytosis and its subtypes

    Time frame: Through completion of the study

Other outcomes

  1. Improve the collective understanding of the natural history of mastocytosis and its impact on patients

    Time frame: Through completion of the study

  2. Assist in the development of mastocytosis therapy by increasing participation in clinical trials and other research studies for patients with mastocytosis

    Time frame: Through completion of the study

Sponsors and collaborators

Lead sponsor

Blueprint Medicines Corporation

Industry

Collaborators

  • PatientCrossroads

Registry information

Important dates

Study start
2015
Primary completion
2021
Study completion
2021
First posted
Dec 2, 2015
Registry last updated
Feb 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.